Table 1: Completed Ketogenic Diet Intervention and Cancer Clinical Trials Overview

| Trial ID | Name | Design | N (enrolled) | N (completed) | Cancer Type | Diet | Length | Concurrent Treatment |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|---------------------------------------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-----------------------------------------------------------|------------------------------------------|
| NCT03171506 | Targeted Disruption to Cancer Metabolism Through Dietary Macronutrient Modification | RCT | n=73: n=36 (control), n=37 (KD) | n=45: n=20 (control), n=25 (KD) | Ovarian, Endometrial | KD: 70%:25%:5% [fat:protein:CHO] | 12 weeks | Chemotherapy: control (n=4), KD (n=7) |
| IRCT20171105037259N2 | Effect of Ketogenic diet on patients with locally advanced and metastatic breast cancer | RCT | n=80: n=40 (control), n=40 (KD) | n=60: n=30 (control), n=30 (KD) | Breast | KD: 55%:19%:6% [fat:protein:CHO], 20% from MCT | 12 weeks | Chemotherapy |
| NCT03535701 | Ketogenic Diet and Chemotherapy to Affect Recurrence of Breast Cancer (The KETO-CARE Study) | Parallel Assignment | n=20 | n=17: n=15 (phase 1), n=9 (phase 2) | Breast | dietary fat to satiety | 6 months: 3 months (phase 1), 3 months (phase 2) | Chemotherapy |
| NCT01716468 | A Low-Carbohydrate Diet for Advanced or Metastatic Cancer | Single Group Assignment | n=11 | n = 4 (16 weeks), n=3 (≥16 weeks) | Prostate, Skin, Renal cell, Pancreatic, Colon, Thyroid, Head and Neck, Lung | MAD: 20-40 g/day CHO | 4-16 weeks | None |
| NCT03075514 | Ketogenic Diets as an Adjuvant Therapy in Glioblastoma: A Randomized Pilot Trial | Parallel Assignment (randomized) | (MKD)) | n=4 (12 weeks): n=3 (MCTKD), n=1 (MKD). n=3 (12 months): n=2 (MCTKD), n=1 (MKD) | multiforme | MKD: 80% fat, 5% CHO. MCTKD: 75% fat (30% via MCT), 10% CHO | 12 weeks/12 months | Chemoradiation |
| N/A | The Impact of a Ketogenic Dietary Intervention on the Quality of Life of Stage II and III Cancer Patients: A Randomized Controlled Trial in the Caribbean | RCT | n=40: n=20 (control), n=20 (KD) | n=36: n=20 (control), n=16 (KD) | Breast, Prostate, Colon/rectal, Cervical, Lung | MKD: 75%15%:10% [fat:protein:CHO] | 16 weeks | Chemotherapy or Radiotherapy |
| N/A | Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial | Single Group Assignment | n=16 | n=5 (completed intervention), n=7 (included in analysis) | Esophagus, | KD: <70 g/day CHO. Oil protein/fat shake (21g:14g:5g) (fat:protein:CHO), 2 times daily | 12 weeks | None |
| NCT00444054 | Pilot Feasibility Study Of A Low Carbohydrate Diet In Patients With Advanced Cancer | Single Group Assignment | n=12 | n=10 | Breast, Fallopian tube, Colorectum, Lung, Esophagus, Ovarian | IID: <5% CHO for energy intake | 26-28 days | None |

| NCT01865162/NCT02302235 | Adjunctive Treatment in Refractory/End- stage Glioblastoma Multiforme: a Pilot Study/Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study | | n=8: n=4 (newly diagnosed GBM), n=4 (recurrent GBM) | n=5: n=4 (newly diagnosed GBM), n=1 (recurrent GBM) | multiforme | KD: 4:1 [fat:protein+CHO], 10 g/day CHO | 6 months | Chemoradiation |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|--------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------|------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------|
| NTR5167 | Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study | Assignment | n=9 | n=6 | Glioblastoma multiforme | KD: 4:1 [fat:protein+CHO] fluid (6 weeks), 1.5-2:1 KD [fat:protein+CHO] w/ 70% MCT supplement (6 weeks) | 14 weeks | Chemoradiation |
| NCT00575146 | _ | Single Group Assignment | n=20 | n=17 | Glioblastoma multiforme | KD: <60 g/day CHO, Highly fermented yogurt (500 mL/day), Plant oils (basic and addition oils) | 12-32 weeks | Chemotherapy |
| NCT02516501 | Investigating the Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition: A Pilot Trial | | n=63: n=31 (control), n=32 (KD) | n=59: n=30 (control), n=29 (KD) | Breast | KD: 75-85% fat, <50 g/day CHO, 10 g/meal CHO | 35 days (median study duration in KD group), 19-47 days (range) | |
| NCT02516501 | Investigating the Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition: A Pilot Trial | | n=49: n=25 (control), n=24 (KD) | n=41: n=23 (control), n=18 (KD) | Rectal | KD: ≤50 g/day CHO | 37 days (median study duration in KD group), 31-43 days (range) | |
| NCT02516501 | Investigating the Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition: A Pilot Trial | | n=32: n=21 (control), n=11 (KD) | n=28: n=21 (control), n=7 (KD) | Head and neck | KD: ≤50 g/day CHO | 39 days (median study duration in KD group), 35-46 days (range) | |
| NCT04631445 | + | RCT | n=32: n=16 (control), n=16 (KD) | N/A | Pancreatic | MSKD: not specified | N/A | Chemotherapy |

| | Advanced Pancreatic Cancer | | | | | | | |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------|
| NCT02286167 | The Feasibility and Biologic Effect of a Modified Atkins-based Intermittent Fasting Diet in Patients With Glioblastoma (GBM) | Single Group Assignment | n=25 | n=21 | Glioma | MAD: ≤ 50 g CHO, 20% of recommended daily caloric intake (5 days); KD: 4:1 [fat:protein+CHO] liquid (KetoCal drink) (2 days, nonconsecutive fasting) | 8 weeks | None |
| NCT03194516 | A Ketogenic Diet Pilot Study for Overweight Prostate Cancer Patients on Active Surveillance | | n=10 | n=10 | Prostate | KD: 3:1 [fat:protein+CHO] | 8 weeks | None |
| NCT02092753 | Ketogenic Or LOGI Diet In a Breast Cancer Rehabilitation Intervention (KOLIBRI) | Parallel Assignment | n=153: n=30 (control), n=93 (LCD), n=30 (KD) | n=121: n=25 (control), n=76 (LCD), n=20 (KD) | Breast | KD: 75% fat, 1.4g/kg /day body weight protein, 20-30 g/day CHO | 20 weeks | None |
| NCT01092247 | The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress | Parallel Assignment | n=9: n=4 (control), n=5 (KD) | n=9: n=4 (control), n=5 (KD) | Glioblastoma multiforme, Gliomatosis cerebri | KD: 4:1 [fat:protein+CHO] | 2-31 months | Bevacizumab |
| NCT02964806 | The Potential Use of a Ketogenic Diet in Pancreatobiliary Cancer Patients After Pancreatectomy | Crossover Assignment | n=30: n=10 (control), n=20 (KD) | n=19: n=9 (control), n=10 (KD) | Pancreatobiliary | KD: 1.05-1.75:1 [fat:protein+CHO] | ~1 month | None |

LCD=low carbohydrate diet

MSKD=medically supervised ketogenic diet

IID=insulin-inhibiting diet

MCTKD=medium-chain triglyceride ketogenic diet

MKD=modified ketogenic diet

MAD=modified Atkins diet

WFKD=well-formulated ketogenic diet

KD=ketogenic diet

RCT=randomized controlled trial